| Q40730575 | 2-CAT: 2-concentric arc technique |
| Q36324701 | 21 years of biologically effective dose |
| Q71223810 | A new isoeffect curve for change in dose per fraction |
| Q33501799 | A phase I study of daily carboplatin and simultaneous accelerated, hyperfractionated chest irradiation in patients with regionally inoperable non-small cell lung cancer |
| Q73915268 | A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study) |
| Q33329945 | A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme |
| Q69834255 | A pilot study of whole body hyperthermia and local irradiation for advanced non-small cell lung cancer confined to the thorax |
| Q40766140 | ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the european organization for research and treatment of cancer (EORTC). |
| Q48926304 | Accelerated fractionation radiotherapy for hospitalized glioblastoma multiforme patients with poor prognostic factors |
| Q91925586 | Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma |
| Q72065621 | Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer |
| Q43620585 | Accelerated radiation therapy for locally advanced squamous cell carcinomas of the oral cavity and oropharynx selected according to tumor cell kinetics--a phase II multicenter study |
| Q90511280 | Altered fractionation diminishes importance of tumor volume in oropharyngeal cancer: Subgroup analysis of ARTSCAN-trial |
| Q36644686 | Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery |
| Q67832622 | Assessment of Human Tumour Proliferation Using Bromodeoxyuridine—Current Status |
| Q36468064 | Back to the future--radiotherapy in high grade gliomas |
| Q41098051 | Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part II: Oncology, chemotherapy and carcinogenesis |
| Q44532636 | Carcinoma of the nasopharynx: analysis of treatment results in 167 consecutively admitted patients |
| Q71223786 | Causes of failure of radiotherapy in head and neck cancer |
| Q67867655 | Comments on “predicting normal tissue injury in radiation therapy” |
| Q74723144 | Comparison of the response of human FaDu squamous cell carcinoma in nude mice after hypofractionated-accelerated regimens and "curative" fractionation schedules |
| Q93600542 | Concomitant boost radiotherapy for advanced squamous cell carcinoma of the head and neck |
| Q36611240 | Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-up |
| Q33498616 | Concurrent daily carboplatin and accelerated hyperfractionated thoracic radiotherapy in locally advanced nonsmall cell lung cancer |
| Q40163039 | Current concepts in radiotherapy and their impact on oncology |
| Q30234489 | Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era. |
| Q34384415 | Dose and fractionation concepts in the primary radiotherapy of non-small cell lung cancer. |
| Q82674746 | Dramatic and prolonged decrease of whole salivary secretion in nasopharyngeal carcinoma patients treated with radiotherapy |
| Q71868200 | Effect of overall treatment time on local control in radical radiotherapy for squamous cell carcinoma of esophagus |
| Q36619918 | Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of sigma-2 receptors in proliferating and quiescent tumour cells |
| Q69011475 | Effective palliation of advanced non-small cell lung cancer by short duration irradiation |
| Q36611916 | Exploring two two-edged swords |
| Q73551660 | Feasibility and outcome of a progressively accelerated concomitant boost radiotherapy schedule for head and neck carcinomas |
| Q72399849 | Fractionated Radiation Therapy after Strandqvist |
| Q51445771 | Gender-related differences in repopulation and early tumor response to preoperative radiotherapy in rectal cancer patients. |
| Q36347857 | Hyperfractionated radiotherapy in brain stem tumors: results of a Pediatric Oncology Group study |
| Q32088985 | Hyperfractionated radiotherapy in head and neck cancer: a second look at the clinical data |
| Q73090135 | Hyperfractionation in carcinoma of the cervix: tumor control and late bowel complications |
| Q34239497 | Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study |
| Q69923630 | Irradiation therapy with multiple small fractions per day in urinary bladder cancer |
| Q40151365 | Keynote address: The scientific basis of the present and future practice of clinical radiotherapy |
| Q53802293 | Lack of influence of sequence of top-up doses on repair kinetics in rat spinal cord. |
| Q68547184 | Late functional, biochemical and histological changes in the rat lung after fractionated irradiation to the whole thorax |
| Q41159751 | Locally advanced non-small cell lung cancer: the "local" issue |
| Q34584856 | Locoregional treatment outcomes after multimodality management of inflammatory breast cancer |
| Q36466684 | Measurement of cell kinetics in human tumours in vivo using bromodeoxyuridine incorporation and flow cytometry |
| Q48632169 | Misonidazole combined with hyperfractionation in the management of malignant glioma |
| Q58122207 | Model-Supported Radiotherapy Personalization: Test of Hyper- and Hypo-Fractionation Effects |
| Q34140922 | Multiple daily fractionation radiotherapy schedules in lung cancer. |
| Q68327767 | Multiple fraction per day radiation therapy for inoperable esophageal cancer |
| Q36745997 | Multiple fraction-per-day radiotherapy for patients with brain stem tumors |
| Q39732623 | Multiple fractions per day in retrospect; the L-Q model and the tolerance profile |
| Q55483325 | Multiple-fraction-per-day external beam radiotherapy for adults with supratentorial malignant gliomas |
| Q48100633 | NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients |
| Q49629456 | Neoadjuvant hyperfractionated accelerated radiotherapy plus concomitant 5-fluorouracil infusion in locally advanced rectal cancer: A phase II study |
| Q34150508 | Non-small cell lung cancer and CHART (continuous hyperfractionated accelerated radiotherapy)--where do we stand? |
| Q81149376 | Non-small-cell lung cancer: reirradiation for loco-regional relapse previously treated with radiation therapy |
| Q39257416 | PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice |
| Q79750655 | Pathologic complete response may not represent the optimal surrogate for survival after preoperative therapy for esophageal cancer |
| Q93600550 | Patterns of cell loss and repopulation in irradiated cultures of plateau phase C3H 10T 1/2 cells |
| Q55484778 | Pediatric brainstem glioma. Post-radiation clinical and MR follow-up. |
| Q77392318 | Phase II evaluation of high dose accelerated radiotherapy for anaplastic thyroid carcinoma |
| Q30660196 | Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineli |
| Q68913465 | Postoperative radiotherapy of carcinoma in bilharzial bladder using a three-fractions per day regimen |
| Q63406398 | Potential doubling time and clinical outcome in head and neck squamous cell carcinoma treated with 70 GY in 7 weeks |
| Q33329329 | Pre-irradiation carboplatin and etoposide and accelerated hyperfractionated radiation therapy in patients with high-grade astrocytomas: a phase II study |
| Q31857384 | Predictive factors in radiotherapy for non-small cell lung cancer: present status. |
| Q73551656 | Predictive value of potential doubling time in head and neck cancer patients treated by conventional radiotherapy |
| Q52426866 | Primary radiotherapy of squamous cell carcinoma of the oropharynx and pharyngolarynx: Tentative multivariate modelling system to predict the radiocurability of neck nodes |
| Q52631475 | Radiobiological considerations in the treatment of neuroblastoma by total body irradiation. |
| Q48716370 | Radiosurgery and accelerated radiotherapy for patients with glioblastoma |
| Q44239807 | Recovery Kinetics of X-ray Damage in Mouse Skin: The Influence of Dose Per Fraction |
| Q39739969 | Regional outcome in oropharyngeal and pharyngolaryngeal cancer treated with high dose per fraction radiotherapy. Analysis of neck disease response in 1646 cases |
| Q46727522 | Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma |
| Q36621308 | Sigma-2 receptors as a biomarker of proliferation in solid tumours |
| Q41131696 | Strategies in the treatment of diffuse pontine gliomas: the therapeutic role of hyperfractionated radiotherapy and chemotherapy |
| Q37182988 | The ESTRO Regaud Lecture Head and neck cancer and the radiation oncologist |
| Q40169933 | The first James Kirk memorial lecture. What next in fractionated radiotherapy? |
| Q48540950 | The second Klaas Breur memorial lecture. La Ronde--radiation sciences and medical radiology |
| Q54147600 | The use of a concomitant electron boost (field in the field technique) in large cervical node metastases over a shortened period. |
| Q42171003 | Tissue repair capacity and repair kinetics deduced from multifractionated or continuous irradiation regimens with incomplete repair. |
| Q72713961 | Tumor cell kinetics in mixed populations |
| Q41788351 | Tumour growth rates in squamous carcinoma of the head and neck measured by in vivo bromodeoxyuridine incorporation and flow cytometry |
| Q41961530 | Tumour proliferation assessed by combined histological and flow cytometric analysis: implications for therapy in squamous cell carcinoma in the head and neck |
| Q73703536 | Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer |
| Q70065212 | What is known about tumour proliferation rates to choose between accelerated fractionation or hyperfractionation? |